Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579423 · ClinicalTrials.gov registry record · Phase 2
Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00579423: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00579423 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00579423, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a pilot trial designed to assess safety and immunogenicity of a multivalent conjugate vaccine for use in patients with biochemically relapsed prostate cancer.
Interventions
- BIOLOGICAL QS21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-11 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00579423
The ClinicalTrials.gov registry entry for NCT00579423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QS21 is the first listed.
NCT00579423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00579423 about?
NCT00579423 is a clinical study titled "Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer". This is a pilot trial designed to assess safety and immunogenicity of a multivalent conjugate vaccine for use in patients with biochemically relapsed prostate cancer.
What is the current status of trial NCT00579423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2000-11. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00579423?
The interventions under investigation include: QS21 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00579423?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.